CAN HYPOFRACTIONATED REIRRADIATION PLUS TEMOZOLAMIDE BE A WISE CHOICE FOR RECURRENT HIGH AND LOW GRADE BRAIN TUMORS?

Ataman, 2004, Quality assurance of the EORTC 26981/22981; NCIC CE3 intergroup trial on radiotherapy with or without temozolomide for newly-diagnosed glioblastoma multiforme: The individual case review, European Journal of Cancer, 40, 1724, 10.1016/j.ejca.2004.03.026 Brandes, 1996, The role of chemotherapy in recurrent malignant gliomas: An overview, Cancer Investigation, 14, 551, 10.3109/07357909609076900 Bräutigam, 2019, Re-irradiation of recurrent glioblastoma as part of a sequential multimodality treatment concept, Clinical and Translational Oncology, 21, 582, 10.1007/s12094-018-1957-6 Chan, 2005, Treatment of recurrent glioblastoma multiforme with GliaSite brachytherapy, International Journal of Radiation Oncology*Biology*Physics, 62, 1133, 10.1016/j.ijrobp.2004.12.032 Cho, 1999, Single dose versus fractionated stereotactic radiotherapy for recurrent high-grade gliomas, International Journal of Radiation Oncology*Biology*Physics, 45, 1133, 10.1016/S0360-3016(99)00336-3 Combs, 2008, Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas, Journal of Neuro-Oncology, 89, 205, 10.1007/s11060-008-9607-4 Combs, 2005, Temozolomide combined with irradiation as postoperative treatment of primary glioblastoma multiforme. Phase I/II study, Strahlentherapie Und Onkologie, 181, 372, 10.1007/s00066-005-1359-x Combs, 2005, Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: Long-term results in 172 patients treated in a single institution, Journal of Clinical Oncology, 23, 8863, 10.1200/JCO.2005.03.4157 Dong, 2016, Re-irradiation alternatives for recurrent high-grade glioma, Oncology Letters, 12, 2261, 10.3892/ol.2016.4926 Hervey-Jumper, 2014, Reoperation for recurrent high-grade glioma: A current perspective of the literature, Neurosurgery, 75, 491, 10.1227/NEU.0000000000000486 Kazmi, 2019, Re-irradiation for recurrent glioblastoma (GBM): A systematic review and meta-analysis, Journal of Neuro-Oncology, 142, 79, 10.1007/s11060-018-03064-0 Korones, 2003, Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma, Cancer, 97, 1963, 10.1002/cncr.11260 Krauze, 2017, Expert consensus on re-irradiation for recurrent glioma, Radiation Oncology, 12, 194, 10.1186/s13014-017-0928-3 Krauze, 2017, Re-irradiation for recurrent glioma- the NCI experience in tumor control, OAR toxicity and proposal of a novel prognostic scoring system, Radiation Oncology, 12, 191, 10.1186/s13014-017-0930-9 Leibel, 1989, Survival and quality of life after interstitial implantation of removable high-activity iodine-125 sources for the treatment of patients with recurrent malignant gliomas, International Journal of Radiation Oncology*Biology*Physics, 17, 1129, 10.1016/0360-3016(89)90518-X Levin, 1990, Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report, International Journal of Radiation Oncology*Biology*Physics, 18, 321, 10.1016/0360-3016(90)90096-3 Mayer, 2008, Reirradiation tolerance of the human brain, International Journal of Radiation Oncology*Biology*Physics, 70, 1350, 10.1016/j.ijrobp.2007.08.015 Minniti, 2011, Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma, Journal of Neuro-Oncology, 103, 683, 10.1007/s11060-010-0446-8 Mirimanoff, 2006, Radiotherapy and temozolomide for newly diagnosed glioblastoma: Recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial, Journal of Clinical Oncology, 24, 2563, 10.1200/JCO.2005.04.5963 Navarria, 2019, Re-irradiation for recurrent glioma: Outcome evaluation, toxicity and prognostic factors assessment. A multicenter study of the radiation oncology italian association (AIRO), Journal of Neuro-Oncology, 142, 59, 10.1007/s11060-018-03059-x Nieder, 2016, Re-irradiation for recurrent primary brain tumors, Anticancer Research, 36, 4985, 10.21873/anticanres.11067 Park, 2000, Survival after stereotactic radiosurgery for recurrent glioblastoma multiforme, Journal of Radiosurgery, 3, 169, 10.1023/A:1009542525044 Paul, 2018, Re-irradiation in central nervous system tumors, Journal of Current Oncology, 1, 40, 10.4103/jco.jco_11_17 Scholtyssek, 2013, Reirradiation in progressive high-grade gliomas: Outcome, role of concurrent chemotherapy, prognostic factors and validation of a new prognostic score with an independent patient cohort, Radiation Oncology, 8, 161, 10.1186/1748-717X-8-161 Shen, 2018, Re-irradiation for malignant glioma: Toward patient selection and defining treatment parameters for salvage, Advances in Radiation Oncology, 3, 582, 10.1016/j.adro.2018.06.005 Shepherd, 1997, Hypofractionated stereotactic radiotherapy in the management of recurrent glioma, International Journal of Radiation Oncology*Biology*Physics, 37, 393, 10.1016/S0360-3016(96)00455-5 Shi, 2018, Investigating the effect of reirradiation or systemic therapy in patients with glioblastoma after tumor progression: A secondary analysis of nrg oncology/radiation therapy oncology group trial 0525, International Journal of Radiation Oncology*Biology*Physics, 100, 38, 10.1016/j.ijrobp.2017.08.038 Shrieve, 1995, Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme, Neurosurgery, 36, 275, 10.1227/00006123-199502000-00006 Stupp, 2005, European organisation for research and treatment of cancer brain tumor and radiotherapy groups; National cancer institute of canada clinical trials group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, New England Journal of Medicine, 352, 987, 10.1056/NEJMoa043330 Torok, 2011, Re-irradiation with radiosurgery for recurrent glioblastoma multiforme, Technology in Cancer Research & Treatment, 10, 253, 10.7785/tcrt.2012.500200 Veninga, 2001, Reirradiation of primary brain tumours: Survival, clinical response and prognostic factors, Radiotherapy and Oncology, 59, 127, 10.1016/S0167-8140(01)00299-7